Introduction {#Sec1}
============

Osteoporosis remains a major health problem worldwide influencing patient's health-related quality of life, mortality, and representing a substantial economic burden on society. The burden of osteoporosis is further expected to increase as a result of the aging population \[[@CR1], [@CR2]\]. Osteoporosis medications have shown to be effective in fracture risk reduction \[[@CR3]\]; however, it is well known that adherence to osteoporosis medications is poor and suboptimal, varying from 34 to 75% in the first year of treatment \[[@CR4], [@CR5]\]. Persistence levels at 1 year were estimated between 18 and 75% \[[@CR6]\]. This suboptimal adherence and persistence leads to increased fracture rate (up to 30%) and worse health outcomes (more subsequent fractures, lower quality of life, and higher mortality), substantially deteriorating the cost-effectiveness resulting from these medications \[[@CR7], [@CR8]\].

Improving adherence to osteoporosis medications is therefore needed but this remains a challenging task. Many factors of non-adherence and non-persistence to osteoporosis medications have been identified such as older age, polypharmacy, side effects, and lack of patient education. Reasons for non-adherence are thus numerous and multidimensional, varying for each patient \[[@CR9]\]. Several interventions and programs have therefore been developed to improve osteoporosis medications adherence. A previous systematic literature review (SLR) published in 2012 noted several promising interventions to improve osteoporosis medication adherence and persistence, such as drug regimen and patient support, automatic electronic prescription, and pharmacist intervention \[[@CR10]\]. This SLR, limited to articles published up to June 2012, further revealed a limited number of studies, the lack of rigorous evaluation of clinical effectiveness, and therefore the need for further studies \[[@CR10]\].

Since this SLR, theories and practical experience on adherence and adherence interventions have evolved \[[@CR11]\]. Moreover, the methodological quality of non-pharmacological interventions has overall improved. This, together with continuing low adherence to anti-osteoporosis medications \[[@CR12]\], the frequent access to the previous SLR, and the publications of several new adherence interventions preceding this study, justifies an update \[[@CR10]\].

For this updated review, it was aimed to appraise studies concerning interventions to improve adherence and persistence to medications for osteoporosis patients in primary of secondary care, published between July 2012 and December 2018.

Methods {#Sec2}
=======

This systematic review was executed in accordance with the PRISMA statement and with the use of a review protocol \[[@CR13], [@CR14]\]. The protocol for this systematic review was registered in PROSPERO (unique ID number: 97472, available on <https://www.crd.york.ac.uk/prospero/>).

Search strategy {#Sec3}
---------------

With the help of an expert library specialist, a comprehensive systematic literature search was designed and performed in Medline (using PubMed), Embase (using Ovid), Cochrane Library, Current Controlled Trials, [ClinicalTrials.gov](http://clinicaltrials.gov), NHS Centre for Review and Dissemination, CINHAL, and PsycINFO. Reference list of identified articles were then manually searched, and forward reference searching was conducted in Web of Science. Detailed search strategies can be found in Appendix [1](#Sec21){ref-type="sec"}.

Selection criteria {#Sec4}
------------------

Articles were included if they met the following eligibility criteria: (1) original study which assessed the effects of interventions aimed on improving adherence or persistence of osteoporosis medications, (2) publication date between July 1, 2012, and December 31, 2018 (the search was restricted to this period to provide an update of the previously published SLR \[[@CR10]\]), and (3) available in English language. Conference proceedings were not included.

The selection of articles was performed in a standardized manner in a three-step process. First, duplicate records were deleted. Second, articles were analyzed by screening the title and abstract (DC). In case of doubt, the article was included for full-text review. Third, full texts were independently reviewed on the eligibility criteria by two authors (DC and SdK). If necessary, consensus was reached by both authors through discussion with a third author (MH).

Definitions of adherence and persistence {#Sec5}
----------------------------------------

Adherence and persistence to medications have been defined differently in several ways \[[@CR15]\]. For organizing data for this review, the following ABC taxonomy, according to Vrijens et al., was followed \[[@CR16]\]. Medication adherence consists of the three following quantifiable phases: (A) initiation (when the patient takes the first dose of a prescribed medication), (B) implementation (the extent to which a patient's actual dosing corresponds to the prescribed dosing regimen, from initiation until the last dose), and (C) discontinuation (when the patient stops taking the prescribed medication, for whatever reason(s)). Persistence is defined as the length of time between initiation and the last dose, which immediately precedes discontinuation \[[@CR16]\].

Extracted information {#Sec6}
---------------------

Data from the included studies were independently extracted by two authors (DC and SdK) in a predesigned data abstraction sheet. A third author (LS) checked independently all extracted data. General information including author, year of publication, country, and setting (primary care, secondary care, or other) were first collected, then the intervention specialist (GP, medical specialist, pharmacist, or other), type of study, population, sample size, outcome measurements (adherence or persistence), type of intervention, and follow-up time.

### Type of interventions {#Sec7}

Interventions extracted from data were classified into four categories based on previous studies \[[@CR10], [@CR12]\]: (1) patient education (provision of information), (2) drug regimen, (3) monitoring and supervision, and (4) interdisciplinary collaboration. These interventions were frequently combined with patient counseling (advice and debate on provided information focused on the individual patient). These modalities could be administered as a single- or multicomponent intervention. In this review, a multicomponent intervention halters two different types of components, e.g., provision of educational material and patient counseling, whereas a single component solely uses one intervention.

Study quality {#Sec8}
-------------

Risk of bias of the included studies was assessed by two researchers (DC and SdK) with the Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) or the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) assessment tool \[[@CR17], [@CR18]\]. To assess study quality, different quality appraisal tools were used specifically designed for each type of study. For observational studies, the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) tool \[[@CR19]\] was used. For clinical trials, the Consolidated Standards of Reporting Trials (CONSORT) tool \[[@CR20]\] was used. Two researchers (DC and VW) independently evaluated the selected studies. A third researcher (LS) randomly checked four appraisals as additional check. All differences were resolved by consensus through discussion.

Synthesis of results {#Sec9}
--------------------

Due to the expected heterogeneity in the methods of adherence measurement and of study outcomes, the analysis was focused on a qualitative assessment, and no meta-analysis was conducted.

Results {#Sec10}
=======

Literature search {#Sec11}
-----------------

After deletion of duplicate records, our search resulted in 585 articles, of which 55 passed the abstract and title screening (Fig. [1](#Fig1){ref-type="fig"}). After full-text assessment, 40 articles were excluded because of the following reasons: no full text available (*n* = 8), not specific for osteoporosis patients (*n* = 1), review article (*n* = 2), lack of a medication adherence intervention (*n* = 22), conference proceedings (*n* = 4), published before July 1, 2012 (*n* = 2), and methodologic article (*n* = 1), resulting in 15 articles. The PRISMA flow chart is presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1PRIMSA flow chart

Study characteristics {#Sec12}
---------------------

The main study characteristics can be found in Table [1](#Tab1){ref-type="table"}. Twelve studies were randomized controlled trials (RCT) \[[@CR21]--[@CR31]\] of which one was a cross-over RCT design \[[@CR32]\]. Other studies were non-randomized, uncontrolled studies \[[@CR33]--[@CR35]\]. A total of 162,804 patients were included, 155,803 in the intervention group and 7001 control patient \[[@CR30], [@CR35]\]. There was a large difference in sample sizes varying from 79 to 147,071 \[[@CR28], [@CR35]\]. Ninety-five percent of patients came from two studies \[[@CR24], [@CR35]\]. The majority of patients were female, and eight studies included solely females \[[@CR22], [@CR25]--[@CR28], [@CR30], [@CR32]\]. Seven studies were European \[[@CR22], [@CR26], [@CR27], [@CR30]--[@CR33]\], five studies North-American \[[@CR24], [@CR25], [@CR29], [@CR34], [@CR35]\], two from Australia \[[@CR21], [@CR28]\], and one from Japan \[[@CR23]\]. Follow-up time varied from 6 to 24 months \[[@CR21], [@CR28]\]. Interventions were executed in secondary care (*n* = 13) \[[@CR22]--[@CR32], [@CR34], [@CR35]\], primary care (*n* = 1) \[[@CR33]\], or in both primary and secondary care (*n* = 1) \[[@CR21]\]. Seven of the 15 interventions were conducted by either physicians and/or nurses/nurse practitioners (*n* = 7) \[[@CR21], [@CR24], [@CR26]--[@CR28], [@CR31], [@CR34]\]. Other interventions were conducted by trained coordinators (*n* = 1) \[[@CR35]\], medical secretaries (*n* = 1) \[[@CR22]\], pharmacists (*n* = 1) \[[@CR33]\], or a combination of physicians and allied healthcare workers (*n* = 1) \[[@CR36]\]. Four studies did not report by whom the intervention was conducted \[[@CR23], [@CR25], [@CR30], [@CR32]\].Table 1The main study characteristicsAuthorCountryYearSettingStudy designInclusion criteriaNumber of patients includedPlanned follow-upAdministered byPatient education1Roux et al.Canada2013Secondary careRCTAged ≥ 50 years with a fragility fractureI~1~ 370I~2~ 311C 20012 monthsAllied health professionals and primary care physicians2Tüzün et al.Turkey2013Secondary careRCTWomen aged between 45 and 75 years with postmenopausal osteoporosis and eligible for oral bisphosphonatesI~1~ 222I~2~ 226C NR12 monthsNR3Bianchi et al.Italy2015Secondary careRCTFemales aged 45--80 years, diagnosed with post-menopausal osteoporosis, receiving a first prescription of an oral drug for OPI~1~ 110I~2~ 111C 11312 monthsHospital staff (physicians and nurses)4Cram et al.USA2016Secondary careRCTAged ≥ 50 presenting for DXA.I 3.917C 3.86512 weeksPhysicians, nurse practitioners, and physician assistants5Gonnelli et al.Italy2016Secondary careRCTOsteoporotic woman aged ≥ 50 receiving a prescription of an oral osteoporosis medication for the first timeI 402C 41412 monthsPhysician NS6LeBlanc et al.Australia2016Secondary careRCTEnglish speaking woman aged ≥ 50 with a diagnosis of osteopenia or osteoporosis, not taking anti-osteoporotic medicationI~1~ 33I~2~ 32C 146 monthsNurse practitioners and physician assistants7Seuffert et al.USA2016Secondary careObservational studyPatients with osteoporosis or osteopenia diagnosed after DXAI 447C 34712 monthsNurse practitioner8Beaton et al.Canada2017Secondary careCohort studyFragility fracture patients (≥ 50 years; hip, humerus, forearm, spine, or pelvis fracture)I 147.071C NR12 monthsA trained coordinator9Danila et al.USA2018Secondary careRCTWomen with self-reported fracture history after age 45 years not using osteoporosis therapyI 1.342C 1.34218 monthsNRDrug regimen10Stuurman-Bieze et al.The Netherlands2014Primary care (pharmacist)Intervention studyPatients initiating osteoporosis medication or a fixed combination with supplementsI 495C 44212 monthsPharmacist11Oral et al.Turkey and Poland2015Secondary careCrossover RCTWomen with postmenopausal osteoporosis aged 55 to 85 years, eligible for anti-osteoporosis treatmentI/C 448^1^26 weeksNR12Tamechika et al.Japan2018Secondary careRCTSystemic rheumatic diseases aged ≥ 20 years, receiving systemic glucocorticoid treatment or risedronate tabletsI 74C 7176 weeksNRMonitoring and supervision13Ducoulombier et al.France2015Secondary careRCTWomen aged \> 50 years, a documented osteoporosis-related fracture warranting initiation of an oral anti-osteoporosis treatmentI 79C 8512 monthsMedical secretaries14van den Berg et al.Netherlands2018Secondary careRCTFemale aged ≥ 50 years attending the FLS due to a recent non-vertebral or clinical vertebral fracture.I 60C 5912 monthsFLS nurseInterdisciplinary collaboration15Ganda et al.Australia2014Primary and secondary careRCTAged \> 45 years and sustained a symptomatic fracture due to minimal traumaI 53C 4924 monthsFLS staff (NS) and PCP*I*, intervention; *C*, control group; *NR*, not reported; *NS*, not specified^1^Patients were their own control

The studied interventions, inclusion and exclusion criteria, and summarized outcomes can be found in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.Table 2The studied interventions and summarized outcomesAuthorInterventionSingle/multicomponent OutcomeDefined asResultsConclusionPatient education and supervision1Roux et al.Intervention group one (I~1~)▪ Educational material▪ Phone callsIntervention group two (I~2~)l▪ Educational material▪ Phone calls▪ Blood tests and BMD test prescription▪ Extra involvement primary care physicianControl▪ Usual careInitiationInitiation of osteoporosis treatment by primary care physician 12 months after a fragility fractureI~1~ vs. C OR 2.5595% CI 1.58--4.12I~2~ vs. C OR 5.0795% CI 3.13--8.21Information and follow-up by primary care physician improved treatment initiation. Additional blood tests and BMD test prescription have no statistically significant effect on treatment initiation.2Tüzün et al.Intervention group one (I~1~)▪ Educational materialIntervention group two (I~2~)▪ Educational material▪ Patient counseling▪ Group meetings▪ Phone callsControl group▪ Not reportedImplementationReceiving treatment as per the instructions of the physician at regular intervals and dosages.I~1~ 49.5%I~2~ 50.5%*p* value 0.86Active or passive training does not improve adherence to anti-osteoporosis medication.DiscontinuationContinuing to receive treatment over the long termI~1~ 43.8%I~2~ 56.2%*p* value 0.483Bianchi et al.Intervention group one (I~1~)▪ Usual care▪ Educational material▪ Alarm clock▪ Suggestions about the use of remindersIntervention group two (I~2~)▪ Usual care▪ Educational material▪ Alarm clock▪ Suggestions about the use of reminders▪ Phone calls▪ Group meetingsControl group▪ Usual careImplementationThe percentage of the prescribed dose takenI~1~ 41%I~2~ 48%C 49%No *p* value providedProviding information and an alarm clock or telephonic reminders and patient meetings does not improve adherence and persistence.PersistenceTaking the medication 10 out of 12 months without pauses longer than 2 weeksI~1~ 90%I~2~ 85%C 92%*p* value 0.294Cram et al.Intervention group one (I~1~)▪ Educational brochure▪ Provision of the test resultsControl group▪ Usual careAdherenceNot definedI~1~ 75.1%C 75.0%No *p* value providedTailored letters providing patients with the DXA score and educational material does not improve adherence.5Gonneli et al.Intervention group one (I~1~)▪ Provision of educational materialControl group▪ Usual careImplementationMorisky Medication Adherence Scale (MMAS) ≥ 75%I~1~ 64.2%C 58.1%No *p* value providedProviding the patients with their individual fracture risk information was not effective to improve adherence or persistence.PersistenceCase reports, not specifiedI~1~ 66.8%C 62.6%No *p* value provided6Leblanc et al.Intervention group one (I~1~)▪ Decision aid discussed during the consultation▪ Patient counselingIntervention group two (I~2~)▪ Provision of FRAX-results▪ Patient counselingControl group▪ Usual careImplementationPercentage of days covered ≥ 80%I~1~ 46.7%I~2~ + C 85%*p* value 0.08Supporting both patients and clinicians during the clinical encounter with the Osteoporosis Choice decision aid does not improve treatment decision-making when compared with usual care with or without clinical decision support with FRAX results.7Seuffert et al.Intervention group one (I~1~)▪ Educational material▪ Provision of the test-results▪ Referral to an endocrinologist when indicatedControl group▪ Usual careImplementationActive treatment 12 months after initiationFemalesI~1~ 95%C 90%*p* value 0.04MalesI~1~ 97%C 82%*p* value 0.04An educational program combined with a referral to an endocrinologist improves the treatment adherence.8Beaton et al.Intervention group one (I~1~)▪ Identification of patients at risk of osteoporosis by a screening coordinator▪ Offering education to both patient and primary care providerImplementationProportion of days covered (PDC) ≥ 50%I~1~ 56.4%C 54.2%*p* value 0.02A screening coordinator does not improve adherence.ImplementationProportion of days covered (PDC) ≥ 80%I~1~ pre intervention 59.9%Post intervention 56.4%*p* value 0.029Danila et al.Intervention group one (I~1~)▪ Provision of educational material containing of video materialControl group▪ Usual careImplementationSelf-report of current osteoporosis medication use at 6 months.I~1~ 11.7%C 11.4%*p* value 0.83A multi-modal tailored direct-to-patient video intervention does not change the adherence to anti-osteoporosis medication or testing.Drug regimen combined with patient support10Stuurman-Bieze et al.Intervention group one (I~1~)▪ Patient counseling▪ Signaling of non-adherence▪ Offering patients an alternative in case of non-adherenceControl group▪ Usual careImplementationMedication possession rate ≤ 80%I~1~ 96.8%C 95.0%*p* value 0.18Counseling sessions by pharmacists did not improve implementation of osteoporosis medication. By providing tailored counseling sessions, pharmacists are able to improve non-discontinuation of anti-osteoporotic medication.DiscontinuationPermanent stopping anti-osteoporosis medicationI~1~ 84.2%C72.2%*p* value \< 0.0111Oral et al.Intervention group one (I~1~)▪ Cross-over medication schemeControl group▪ Usual careImplementation\> 50% dose takenI~1~ 59.9%C 61.9%*p* value 0.46A flexible dosing regimen can improve non-discontinuation of anti-osteoporosis medication. It does however not affect implementation.DiscontinuationContinuation of treatment after 26 weeksI~1~ 86.0%C 78.9%*p* value 0.0312Tamechika et al.Intervention group one (I~1~)▪ Switching from weekly bisphosphonates to monthly minodronateControl group▪ Usual careAdherenceNot definedI~1~ 99.4%C 99.5%No *p* value providedSwitching from weekly bisphosphonates to monthly minodronate does not improve adherence to anti-osteoporosis medication.Monitoring and supervision13Ducoulombier et al.Intervention group one (I~1~)▪ Phone calls▪ Patient counselingControl group▪ Usual careImplementationMedication possession rate ≥ 80%I~1~ 64.6%C 32.9%*p* value \< 0.01Telephonic follow-ups enhance patient's implementation and non-discontinuation.DiscontinuationContinuing to take a medication after 12 monthsI~1~ 72.6%C 50.6%*p* value \< 0.0114van den Berg et al.Intervention group one (I~1~)▪ Phone callsControl group▪ Usual carePersistenceNot definedI~1~ 93.0%C 88.0%No *p* value providedTelephonic follow-up of osteoporosis patients does not improve persistence.Interdisciplinary collaboration15Ganda et al.Intervention group one (I~1~)▪ Transferring the patient to the GP after 3 monthsControl group▪ Usual careImplementationMedication possession rate ≥ 80%I~1~ 64.0%C 61.0%*p* value 0.75Transferring the care from the FLS clinic to the GP has no influence on implementation.*I*, intervention; *C*, control group; *NR*, not reported; *NS*, not specifiedTable 3The study population and setting, inclusion and exclusion criteria and results per type of adherenceAuthorStudy population and settingInclusion criteriaExclusion criteriaActivities and intensity of interventionComponentEffectsPatient education and supervision1Roux et al.Patients who present themselves with a hip fracture or attending the orthopedic fracture clinic at Centre Hospitalier Universitaire de SherbrookeAged ≥ 50 years, hospitalized with a hip fracture or were seen at the orthopedic fracture clinics with a fragility fracturePsychiatric and cognitive problems, language barriersI~1~ Information to patient and primary care physician. Follow-up calls at 6 and 12 months. 2nd intervention if not treated at 6 monthsI~2~ Extra information to patient and primary care physician. Follow-up calls at 4, 8, and 12 months. 2nd intervention if not treated at 6 months. Blood test and BMD prescriptionC Usual careMulti-componentInitiation+ImplementationNRDiscontinuationNRPersistenceNR2Tüzün et al.Women aged between 45 and 75, diagnosis of postmenopausal osteoporosis, eligible for osteoporosis treatment with weekly oral bisphosphonatesCentre NSWomen aged between 45 and 75 years, had a diagnosis of postmenopausal osteoporosis according to WHO criteria, and had a clinical presentation appropriate for osteoporosis treatment with weekly oral bisphosphonatesSecondary osteoporosis, receiving anti-osteoporosis treatmentI~1~ Educational material (booklets osteoporosis in general, osteoporosis and exercise, osteoporosis and nutrition, osteoporosis and patient) at baseline.I~2~ Educational material (booklets osteoporosis in general, osteoporosis and exercise, osteoporosis and nutrition, osteoporosis and patient) at baseline.Group meetings with the topics (1) Osteoporosis in General (2), Osteoporosis and Exercise,( 3) Osteoporosis and Nutrition, and (4) Osteoporosis and Patient Rights3, 6, 9, 12 months.Follow-up phone calls to remind patients to read the information booklets2, 5, 8, 11 monthsMulti-componentInitiationNRImplementation-/-Discontinuation-/-PersistenceNR3Bianchi et al.The study design is a multicenter, prospective, randomized study of women affected by primary post-menopausal osteoporosis, starting oral therapy. Carried out at six Italian hospital centers distributed in Northern. Central and Southern ItalyFemale aged 45--80 years, diagnosis of post-menopausal osteoporosis receiving a prescription of an oral drug for osteoporosis for the first timePossess the ability to read and understand simple educational materials and to answer simple questionnaires, availability for phone calls, and ability to come to the hospital's outpatient clinic for meetingsOn oral therapy at beginning of the study, secondary osteoporosis, affected by other diseases requiring complex drug therapy, severe cognitive, visual, or hearing impairmentI~1~ Usual careTwo booklets providing information on osteoporosis and the importance of adherence to treatment. Colored memo stickers for a calendar or diary, a small alarm clock, suggestions about the use of these reminders to improve adherence to therapyI~2~ Similar to group one with the addition of phone calls (every 3 months) to remind patients to take the medication and invite patients to the informational group meetings (4 meetings during the 12 months)Content of the meetings were not specifiedC Usual care.Multi-componentInitiationNRImplementation-/-DiscontinuationNRPersistence-/-4Cram et al.Patients presenting themselves for a DXA at three health centers, the University of Iowa. the University of Alabama at Birmingham (UAB), and Kaiser Permanente of Georgia (KPGA)Age ≥ 50. presenting for DXAAge \< 50, prisoners, overt cognitive disability, unable to speak or read English, deaf, no access to telephoneI~1~Usual care.Mailed tailored-letter with their DXA results accompanied by an educational brochureC Usual careMulti-componentInitiationNRImplementationNRDiscontinuationNRPersistenceNR5Gonnelli et al.Osteoporotic women aged 50 years or over receiving a prescription of an oral osteoporosis medication for the first time were recruited at 34 Italian outpatient centers (Departments of Internal Medicine. Rheumatology. Rehabilitation and Geriatrics)Women aged ≥ 50 years or over, referred as outpatients for a follow-up visit 12 months after receiving a prescription of an oral osteoporosis medication (bisphosphonates, strontium ranelate, and selective estrogen receptor modulators \[SERMs\]) for the first time. Osteoporosis was defined as a T-score B-2.5 at lumbar spine and/or hip evaluated by dual X-ray absorptiometry (DXA) according to the WHO criteriaPresence of malignancies, multiple myeloma, Paget's disease of bone, hyperparathyroidism, history of alcohol abuse (400 g/week), severe hearing or visual impairment, cognitive problems which would prevent reliable participation to the study, and any history of fragility fractures in the last 12 monthsI~1~Usual careDetailed information about individual fracture risk along with a leaflet containing the absolute fracture risk value by DeFRA algorithm (group 2; *n* = 402)C Usual careMulti-componentInitiationNRImplementation-/-DiscontinuationNRPersistence-/-6LeBlanc et al.Women age over 50 with a diagnosis of osteopenia or osteoporosis from participating practices (family medicine, preventive medicine, primary care internal medicine, and general internal medicine) were all affiliated to the Mayo Clinic (Rochester, MN, USA)Women aged over 50, with a diagnosis of osteopenia or osteoporosis, were not taking bisphosphonates or other prescription medications to treat their condition, were identified by their clinician as potentially eligible for bisphosphonates, were available for a 6-month follow-up after randomization, and had no major learning barriersN/RI~1~ Patients were provided a decision aid consisting their individualized 10-year risk of having a bone fracture estimated using the FRAX calculator and potential side effect of bisphosphonatesI~2~ Clinicians providing patients their individualized 10-year risk of having a bone fracture estimated using the FRAX calculatorC Usual careMulti-componentInitiationNRImplementation-/-DiscontinuationNRPersistenceNR7Seuffert et al.Patients who visit an orthopedic office NS.Patients diagnosed with osteoporosis by DXA (T-score − 2.5 and below) or a recent fragility fracture. Presence of osteopenia was also noted (defined as a T-score between − 1.1 and − 2.5)N/RI~1~ Educated by a nurse practitioner about the DXA results, calcium and vitamin D supplementation, provision of materials (brochures published by the National Osteoporosis Foundation)• C Usual care and a letter with the patients' DXA scoreMulti-componentInitiationNRImplementation+DiscontinuationNRPersistenceNR8Beaton et al.Patients who are identified by the Fracture Clinic Screening Program (FCSP)Fragility fracture patients.Having a prescription filled \< 12 months before the fractureI~1~Identification of patients at risk of osteoporosis, educational material, intensity not specifiedMulti-componentInitiationNRImplementation-/-DiscontinuationNRPersistenceNR9Danila et al.Patients included in the Activating Patients at Risk for OsteoPorOsiS (APRROPOS)-study.Women aged ≥ 45 with a self-reported fractureN/RI~1~ Educational videos emailed and sent through DVD containing an (1) introduction video explaining the reason for receiving the materials, (2) personalized videos addressing barriers to osteoporosis therapy or presenting general osteoporosis information (for those who did not rank barriers to treatment), and (3) a video on "How to communicate with your doctor about bone health"C Usual careSingle-componentInitiationNRImplementation-/-DiscontinuationNRPersistenceNRDrug regimen combined with patient support10Stuurman-Bieze et al.Patients initiating osteoporosis medication, recruited from 13 Dutch community pharmaciesAll patients who initiated osteoporosis medication registered in the participating pharmacies between March 2006 and March 2007N/RI~1~ Patient counseling during the first two dispensary momentsActive monitoring and signaling, 3 months after initiating medication. Non-adherent patients were intervened if warranted.C Usual pharmacy careMulti-componentInitiationNRImplementation-/-Discontinuation+PersistenceNR11Oral et al.Women with post-menopausal osteoporosis enrolled in 10 centers in Turkey and 9 centers in PolandAmbulatory women aged 55 to 85 years, eligible for anti-osteoporosis treatmentN/RI~1~ Switching with drug regimen at 1, 2, 3, and 23 weeks to the preferred regimenSingle-componentInitiationNRImplementation-/-Discontinuation+PersistenceNR12Tamechika et al.Patients with systemic rheumatic disease, aged ≥ 20, receiving systemic glucocorticoid from rheumatology clinics in Nagoya City University Hospital, Kainan Hospital, and Nagoya City West Medical CenterSystemic rheumatic disease, aged ≥ 20 receiving systemic glucocorticoid and weekly oral alendronate or risedronate tablets before screeningTaking bisphosphonates other than weekly oral alendronate or risedronate tablets previously taking parathyroid hormone analogues, denosumab, or other investigational new drugs for the treatment of osteoporosisI~1:~24 weeks bisphosphonates followed by 52 weeks minodronateC Usual careSingle-componentInitiationNRImplementationNRDiscontinuationNRPersistenceNRMonitoring and supervision13Ducoulombier et al.Patients attending a FLSWomen aged ≥ 50 yearsA documented osteoporosis-related fracture warranting initiation of oral osteoporosis medication.Previously used osteoporosis medicationI~1:~Two monthly phone calls lasting 10 min by medical secretaries to detect any difficulties in complying with the treatment and to remind patients to the importance of continuation the treatment as prescribed. When poor adherence was signaled, the secretary advised the patient to consult the primary care physicianC Usual careMulti-componentInitiationNRImplementation+Discontinuation+PersistenceNR14van den Berg et al.Patients attending a FLSFemales aged ≥ 50 years attending the FLS due to a recent non-vertebral or clinical vertebral fractureMetabolic bone disordersI~1:~Phone calls in months 1, 4, and 12 to remind the patient to take the medication and to exchange views on the side effectsC Usual careSingle-componentInitiation NRImplementationNRDiscontinuationNRPersistence-Interdisciplinary collaboration15Ganda et al.Patients attending the FLS-clinicAged \> 45 years and sustained a symptomatic fracture due to minimal traumaUnable to provide informed consent, resided in a nursing home or hostel at the time of the incident fracture, a life expectancy \< 3 years, not having a local medical practitioner, malignant or metabolic bone disease, gastrointestinal malabsorption syndromes, contra-indications to oral antiresorptive therapyI~1:~3 months visit at the FLS21 months care by the primary care providerC Usual care of 24-month follow-up at the FLSSingle-componentInitiationNRImplementation-/-DiscontinuationNRPersistenceNR*I*, intervention; *C*, control group; *NR*, not reported; *NS*, not specified, *-/-*, no effect; *+*, a significant effect

Definition and measures {#Sec13}
-----------------------

### Measures of adherence {#Sec14}

Adherence to prescribed medication was mentioned as an outcome in fourteen studies \[[@CR21]--[@CR25], [@CR27]--[@CR35]\]. Adherence was reported as initiation (*n* = 1), implementation (*n* = 9), and discontinuation (*n* = 4). In two studies, the type of adherence was not described \[[@CR23], [@CR24]\]. Initiation was described as initiation of osteoporosis treatment by primary care physician 12 months after a fragility fracture \[[@CR29]\]. Implementation was described as medication possession rate (MPR) ≥ 80% \[[@CR21], [@CR22], [@CR28], [@CR33], [@CR35]\], a medication possession rate (MPR) ≥ 50% \[[@CR32], [@CR35]\], per the instructions of the physician at regular intervals and dosages \[[@CR30]\], the percentage of the prescribed dose taken \[[@CR27]\], scoring ≥ 75% on the Morisky Medication Adherence Scale (MMAS) \[[@CR31]\], self-report of current osteoporosis medication use at 6 months \[[@CR25]\], or active treatment 12 months after initiation \[[@CR34]\]. Discontinuation was described as continuing to receive treatment over the long term \[[@CR30]\], as permanently stopping anti-osteoporosis medication \[[@CR33]\], continuation of treatment after 26 weeks \[[@CR32]\], or continuing of medication after 1 year \[[@CR22]\]. Persistence was mentioned as an outcome in three studies \[[@CR26], [@CR27], [@CR31]\]. It was described as taking medication 10 out of 12 months without medication gaps longer than 2 weeks \[[@CR27]\]. Two studies did not describe persistence \[[@CR26], [@CR31]\]. In six studies \[[@CR21], [@CR23], [@CR25], [@CR26], [@CR31], [@CR32]\], the effect of a single-component intervention was studied, while nine studies \[[@CR22], [@CR24], [@CR27]--[@CR30], [@CR33]--[@CR35]\] studied a multicomponent intervention.

Questionnaires and/or diaries (*n* = 8) \[[@CR22], [@CR23], [@CR25], [@CR27]--[@CR31]\], and pharmacist databases (*n* = 3) \[[@CR21], [@CR26], [@CR33]\] were the most common sources methods for data collection. Other methods included patient records (*n* = 1) \[[@CR35]\], empty drug boxes (*n* = 1) \[[@CR27]\], laboratory tests (*n* = 1) \[[@CR26]\], collection of medication during a consultation (*n* = 1) \[[@CR32]\], and retrieved from the PAADRN trial (*n* = 1) \[[@CR24], [@CR37]\]. In one study, the authors did not report the method of data collection \[[@CR34]\].

### Patient education {#Sec15}

Nine studies assessed the effects of patient education of which were seven RCTs, one cohort study, and one observational study \[[@CR24], [@CR25], [@CR27]--[@CR31], [@CR34], [@CR35]\]. In these nine studies, adherence was used as an outcome \[[@CR24], [@CR25], [@CR27]--[@CR31], [@CR34], [@CR35]\], and in two studies, persistence was also reported \[[@CR27], [@CR31]\]. Interventions can further be classified into educational sessions (consisted of meetings with 4--6 patients and a psychologist) (*n* = 2) \[[@CR27], [@CR30]\], provision of educational material (*n* = 8) \[[@CR24], [@CR25], [@CR27], [@CR29]--[@CR31], [@CR34], [@CR35]\], and the use of a decision aid (*n* = 1) \[[@CR28]\]. Educational material varied between providing information booklets or flyers \[[@CR24], [@CR25], [@CR27], [@CR29]--[@CR31], [@CR34]\], providing DVDs with visual information regarding the intervention, (treatment of) osteoporosis, and how to discuss this with the physician \[[@CR25]\], or a decision aid which included the personal risk on a fracture \[[@CR28]\]. In seven studies, education was combined with counseling. The way and the intensity of patient counseling varied from offering patients advice and recommendation concerning the educational material \[[@CR35]\] to up to four telephonic follow-up calls combined with 4 group sessions in 12 months \[[@CR30]\].

A significant effect on medication adherence was observed in two of the nine studies, both multicomponent interventions \[[@CR29], [@CR34]\]. One study combining patient education, counseling, blood tests, BMD test prescription, and follow-up phone calls resulted in an increase in adherence between 40 and 53% in the intervention groups, compared with 19% in usual care and odds ratios of 2.55--5.07 \[[@CR29]\]. When an educational program was combined with a referral to an endocrinologist for a consultation, implementation rates improved significantly compared with usual care (for females, intervention 95% vs. control 90%; for males, intervention 97% vs. control 82%; both *p* = 0.04) \[[@CR34]\]. Seven studies were unable to significantly affect adherence to osteoporosis medications or provide a significance level with their results \[[@CR24], [@CR25], [@CR27], [@CR28], [@CR30], [@CR31], [@CR35]\]. Albeit, of these studies, the single-component interventions included solely providing educational material \[[@CR25], [@CR31]\]. The multicomponent interventions included providing patients the DXA score combined with educational material \[[@CR24]\], identification of patients at risk for osteoporosis combined with educational material \[[@CR35]\] providing a decision aid or FRAX results combined with patient counseling \[[@CR28]\], and the more extensive provision of educational material, an alarm clock, phone calls, and patient counseling/group meetings \[[@CR27], [@CR30]\]. In none of the included studies, a significantly positive effect on persistence was described.

### Drug regimen {#Sec16}

Three studies evaluated the effect of alterations in drug regimen compared with usual care. Of these studies, two were RCTs and one was an observational study \[[@CR23], [@CR32], [@CR33]\]. Adherence (not further defined) was the primary outcome in one study \[[@CR23]\], while the two other studies focused on both implementation and discontinuation \[[@CR32], [@CR33]\]. The studies concerned single-component interventions as either offering patients a choice of flexible dosing regimen \[[@CR32]\] or switching to an alternative drug with longer dosing intervals \[[@CR23]\], or multicomponent interventions of a combination of signaling of non-adherence, and offering alternative medication combined with counseling \[[@CR33]\]. None of the studies resulted in a significant improvement of adherence/implementation. There was a significant positive effect on discontinuation in two studies. In one study, a choice of flexible dosing regimen compared with usual care resulted in 86% vs. 79% no discontinuation (*p* = 0.03) \[[@CR32]\], and the combination of signaling of non-adherence with offering alternative medication combined with counseling compared with usual care led to no discontinuation 84% vs. 72% (*p* \< 0.01) \[[@CR33]\].

### Monitoring and supervision {#Sec17}

Monitoring and supervision was investigated in two RCT studies \[[@CR22], [@CR26]\]. Implementation and discontinuation to osteoporosis medications were the outcome in one study \[[@CR22]\] and persistence in the other \[[@CR26]\]. In both studies, patients frequently received telephone calls as a reminder to take their medication as prescribed, compared with usual care. In one study, this was a multicomponent intervention, where the phone calls were combined with patient counseling \[[@CR22]\]. There was a positive effect on both implementation and discontinuation in one study with increased implementation rates of 65% vs. 33% (*p* \< 0.01) and non-discontinuation rates of 73% vs. 51% (*p* \< 0.01) in the intervention group \[[@CR22]\]. Persistence was not significantly affected \[[@CR26]\].

### Interdisciplinary collaboration {#Sec18}

Finally, the influence of setting of care was assessed in one RCT study, with longer term implementation of osteoporosis medications as outcome \[[@CR21]\]. During this single-component study \[[@CR21]\], patients, in whom anti-osteoporosis medication was initiated at the Fracture Liaison Service (FLS), were either allocated after 3 months to further follow up in the FLS (usual care) or transferred to the principal care provider (PCP). After 24 months, there was no difference between the groups in terms of implementation of anti-osteoporosis medications.

Quality assessment {#Sec19}
------------------

The risk of bias was assessed with the RoB 2 or ROBINS-I tool \[[@CR17], [@CR18]\]. The overall risk of bias of the included studies varied from low to high/serious, increased risk of bias concerned missing outcome data and selection of participants. The results are presented in Appendix [2](#Sec22){ref-type="sec"}.

The quality of the three observational studies and twelve RCTs was assessed with the STROBE tool \[[@CR19]\] and with the CONSORT tool \[[@CR38]\], respectively. Overall, the quality of the studies was variable and moderate. The results are presented in Appendix [3](#Sec23){ref-type="sec"}. In general, the setting, eligibility criteria, and the rationale were described well in the observational studies \[[@CR33]--[@CR35]\]. However, sensitivity analysis, handling of missing data, and the sample size calculation were absent in all three studies. The sources of data for each variable fully were only described in one study \[[@CR35]\]. The RCTs were sufficient when considering abstracts, eligibility criteria of the participants, and the statistical analysis. One study reported changes which occurred after the trial commenced \[[@CR28]\]. None of the studies reported any harms and methods of randomization, and allocations were poorly described. Sources of funding were not reported in one study \[[@CR31]\]. In none of the studies, the interventions or data were blinded for the patient, physician, or analyst.

There was no evident difference regarding the risk of bias or study quality, when considering the different types of interventions or between single or multicomponent interventions.

Discussion {#Sec20}
==========

For this updated review, 15 studies and 19 comparisons in which interventions to improve adherence and persistence to osteoporosis medications were assessed. Interventions included patient education, monitoring and supervision, change in drug regimen combined with patient support, and interdisciplinary collaboration.

Different approaches for patient education (combined with counseling) were the most studied interventions, but the effect on adherence was limited. Only two out of nine studies reported significant improvements on implementation and discontinuation \[[@CR29], [@CR34]\], and none of the interventions reported a positive effect on persistence. Change in drug regimen, combined with patient support \[[@CR23], [@CR32], [@CR33]\], did not result in a positive effect on implementation. Furthermore, a significantly positive effect on discontinuation to osteoporosis medications was sorted when patients were offered a choice of flexible dosing regime and a combination of signaling of non-adherence with offering alternative medication combined with counseling. There was a notable difference in patient participation and involvement; if the patient was counseled or offered participation in the choice regarding the decision concerning drug regimen, there was an improvement in no discontinuation \[[@CR32], [@CR33]\], in contrast to no improvement in adherence when the patient was not involved \[[@CR23]\]. This implicates that patient involvement is an important factor to improve medication persistence while employing flexible dosing regimen. Also, since there was no effect on implementation, but an effect on discontinuation, it seems change in drug regimen is only useful for patients already using osteoporosis medications. Monitoring and supervision were shown to have a positive effect on both implementation and discontinuation, but only in one study. In this study, patients were offered counseling, and not solely monitored or supervised \[[@CR22]\]. Finally, there was no difference in terms of persistence to osteoporosis medications when patients were either allocated to the regular FLS for 24 months (usual care) or transferred to the principal care provider (PCP) after 3 months for a follow-up of 21 months \[[@CR21]\]. Although this did not lead to an improvement in medication persistence, it also did not lead to a decrease. This implicates that the role of the rheumatologist can partially be replaced by other physicians making the treatment more flexible.

Compared with the previous SLR, there was a notable difference in interventions; in the included articles for this review, there was more emphasis on patient involvement, counseling, and shared decision-making, hence multicomponent interventions, instead of solely patient information/education or supervision each (single component intervention), and there was a larger variation of healthcare professionals involved in conduction of these interventions. Earlier studies described that patient education had the potential to increase adherence, but new research published since the previous SLR could not confirm this, despite some reasonable effect size, and the effect of solely patient education seems limited \[[@CR39]--[@CR41]\]. Improvement is only expected when it is combined with counseling. Similarities are found when comparing strategies in other chronic diseases, as diabetes; education is seen as the cornerstone which is integrated in each intervention strategy combined with involvement of the healthcare provider and patient, a so-called combined educational-behavioral strategy \[[@CR42]\]. Compared with the previous SLR, an improvement in the quality of studies is observed. Of the fifteen included studies, the majority were randomized controlled trials, mostly of reasonable quality. However, there was heterogeneity in methodology and (reporting of) results, similar to the previous SLR. Risk of bias was variable, from low to high/serious. As in the previous SLR, almost all studies used adherence as outcome, and persistence was less frequently used. The definitions which were used for adherence and persistence still varied greatly; for instance, we found twelve different descriptions of adherence. These findings show that the taxonomy for describing and defining adherence to medications by Vrijens et al. is not fully implemented yet \[[@CR16]\], as was also concluded in the previous SLR.

There was an effect of a change in drug regimen, as reported in earlier studies, in which flexible dosing regimens were effective in increasing adherence, regardless of the level of patient involvement \[[@CR10]\]. However, multicomponent interventions, where a change of drug regimen is combined with counseling, also led to an increase of no discontinuation levels. In the field of neurology, especially migraine/chronic headache, it is emphasized that drug regimens concerning preventive medication should be tailored to lifestyle, to increase adherence, thus also focusing on multicomponent intervention \[[@CR43]\].

Interdisciplinary collaboration was described successful when improving adherence in other studies within the field of osteoporosis or in other diseases \[[@CR44], [@CR45]\], contrary to our findings. However, to lift the burden on medical specialists, interdisciplinary collaboration could be of added value, since there was no decrease of persistence either \[[@CR46]--[@CR48]\].

The currently available data on adherence and persistence to osteoporosis medications have several limitations. First, the available data was mostly self-reported, introducing social desirability and recall bias, or may not be true values due to the use of prescription data and time until last prescription refill \[[@CR6]\]. In addition, this resulted also in an increased risk of bias of missing outcome data.

Second, in none of the studies, the intervention or data were blinded for the patient, physician, or analyst. While this is not always possible, especially for patients, it could result in confirmation bias and selection bias. Third, the follow-up time was limited to a maximum of 24 months; hence, osteoporosis is a chronic disease; this could be of influence on the long-term results of adherence and persistence.

There were strengths and potential issues in relation to the methodology and execution of this review. The search was designed with the help of an expert library specialist. Article selection, data extraction, and quality appraisal were conducted by at least two researchers. Furthermore, the review was executed in accordance with the PRISMA statement. Although we found 15 new adherence intervention studies, the conclusions on adherence interventions remain blurred, and still no clear recommendations regarding interventions to improve medication adherence and persistence can be derived from our review. Moreover, we recognized the same limitations with regard to quality and thus interpretation, comparison, or meta-analyses. In other words, we confirmed variability in definition and measurement of adherence outcome, challenges to classify adherence interventions, and limitations in design related to blinding of patients and/or physicians, sensitivity analysis, handling of missing data, and often sample calculations. Notwithstanding, we feel our review does provide added value by pointing to the direction on which future research should focus, namely, multicomponent interventions with active patient involvement.

With regard to the classification of interventions into four categories, non-homogenous groups are possibly not comparable with other studies/reviews. The ABC taxonomy by Vrijens et al. \[[@CR16]\] was used for organizing and comparing data for this review, resulting in the use of the terms adherence, subdivided in initiation, implementation and discontinuation, and persistence, which sometimes differed compared with the terms used in the original articles. Also, the influence of the health system (e.g., co-payments, reimbursement, and difference in primary and secondary care), which differs per country, was not considered \[[@CR9]\]. In a recent ESCEO paper, different recommendations to improve medication adherence and persistence were drafted by an international working group \[[@CR12]\]. These include patient education and counseling, improving patient interaction and shared-decision making, and dose simplification such as the use of gastro-resistant risedronate tablets that could be taken after breakfast. In addition, the ESCEO working group recognized the need for more evidence and high-quality research and provides recommendations for further research in the field.

In conclusion, this updated review suggests that improving adherence and persistence to osteoporosis medications remains a complex and challenging issue, and no clear recommendations can unfortunately be derived from it. Patient education, monitoring and supervision, change in drug regimen combined with patient support, and interdisciplinary collaboration were shown to have some effect on either adherence or persistence but only in some of the studies. However, interestingly, multicomponent interventions with active patient involvement were the most effective interventions when aiming to increase adherence and/or persistence to osteoporosis medications. It would thus be important to design appropriate multicomponent interventions and to critically evaluate them with means of well-designed randomized controlled trials, ideally with longer follow-up.

Appendix 1 {#Sec21}
==========

**Pubmed**

\"Osteoporosis\"\[Mesh\] OR Osteoporosis \[tiab\] OR \"Bone Diseases, Metabolic\"\[Mesh\] OR

Metabolic Bone Disease\*\[tiab\] OR \"Bone Demineralization, Pathologic\"\[Mesh\] OR Bone

Demineralization\[tiab\] OR \"Decalcification, pathologic\"\[MeSH Terms\] OR Patholog\*

Decalcification\*\[tiab\] OR \"Bone Density\"\[Mesh\] OR Bone Densit\*\[Tiab\]

AND

\"Guideline adherence\"\[MeSH Terms\] OR Guideline adherence\*\[tiab\] OR \"Patient

Satisfaction\"\[Mesh\] OR Patient Satisfaction\[tiab\] OR \"Patient Preference\"\[Mesh\] OR Patient

Preference\*\[tiab\] OR \"Attitude to Health\"\[Mesh\] OR Health attitude\*\[tiab\] OR \"Health

Knowledge, Attitudes Practice\"\[Mesh\] OR \"Treatment Adherence and Compliance\"\[Mesh\] OR

Treatment Adherence \[tiab\] OR Therapeutic adherence \[tiab\] OR "Treatment compliance"\[tiab\]

OR "Therapeutic compliance"\[tiab\] OR \"Patient Acceptance of Health Care\"\[Mesh\] OR \"Patient

Acceptance of Health Care\"\[tiab\] OR \"Patient Dropouts\"\[Mesh\] OR \"Patient dropout\*\"\[tiab\] OR

\"Patient Participation\"\[Mesh\] OR \"Patient Participation\"\[tiab\] OR \"Patient Compliance\"\[Mesh\]

OR Patient Compliance \[tiab\] OR Patient engagement \[tiab\] OR Patient Acceptance \[tiab\] OR

Patient involvement \[tiab\] OR Medication adherence \[tiab\] OR Medication persistence \[tiab\] OR

Medication compliance \[tiab\]

**Embase**

\*metabolic bone disease/ or \*bone disease/ or \*bone demineralization/ or \*osteoporosis/ or

\*bone demineralization/

01-07-2012 t/m 31-12-2018

AND

\*disease management/ or patient attitude/ or \*attitude/ or \*health care quality/ or \*human

relation/ or \*patient attendance/ or \*patient compliance/ or \*patient dropout/ or \*patient

participation/ or \*patient preference/ or \*patient satisfaction/ or \*refusal to participate/ or

\*treatment interruption/ or \*treatment refusal/ or \*protocol compliance/ or \*attitude to

health/ or \*attitude/ or \*health behavior/ or \*knowledge/ or \*attitude to illness/ or \*health

behavior/ or \*behavior/ or \*medication compliance/ or \*patient education/ or \*health

education/

2012-2018

**PSYCHINFO**

(MM \"Treatment Compliance\" OR (MM \"Compliance\" OR MM \"Treatment Compliance\" OR MM

\"Client Attitudes\" OR MM \"Health Attitudes\" OR MM \"Health Behavior\" OR MM \"Health Care

Utilization\" OR MM \"Health Education\" OR MM \"Health Knowledge\" OR MM \"Health Literacy\"

OR MM \"Client Education\" OR MM \"Client Satisfaction\" OR MM \"Client Participation\" OR MM

\"Client Attitudes\" OR MM \"Treatment Refusal\")

AND

(MM \"Osteoporosis\") OR (MM \"Bone Disorders\")

01-07-2012 t/m 31-12-2018

**Cinahl**

(MM \"Guideline Adherence\") OR (MM \"Medication Compliance\") OR (MM \"Patient

Compliance\") OR (MM \"Compliance with Medication Regimen (Saba CCC)\") OR (MM

\"Compliance with Therapeutic Regimen (Saba CCC)\") OR (MM \"Compliance with Medical

Regimen (Saba CCC)\") OR (MM \"Patient Satisfaction\") OR (MM \"Attitude to Illness\") OR (MM

\"Attitude to Medical Treatment\") OR (MM \"Attitude to Health\") OR (MM \"Patient Attitudes\")

OR (MM \"Knowledge: Health Behaviors (Iowa NOC)\") OR (MM \"Knowledge\") OR (MM \"Health

Knowledge\") OR (MM \"Acceptance and Commitment Therapy\") OR (MM \"Patient Dropouts\")

AND

(MM \"Osteoporosis\")

01-07-2012 t/m 31-12-2018
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Table 4Risk of bias (Revised Cochrane risk-of-bias tool for randomized trials (RoB 2))AuthorRouxTüzünBianchiCramGonnelliLeBlancDanilaOralTamechikaDucoulombiervan den BergGandaRisk of BiasDomain 1:Risk of bias arising from the randomization processLowSome concernsLowLowLowLowLowLowLowSome concernsHighLowDomain 2:Risk of bias due to deviations from the intended interventions (effect of adhering to intervention)LowLowLowLowLowHighLowLowLowLowLowLowDomain 3:Missing outcome dataLowHighHighLowSome concernsSome concernsSome concernsLowLowLowHighLowDomain 4:Risk of bias in measurement of the outcomeLowLowLowLowLowLowLowLowLowLowLowLowDomain 5:Risk of bias in selection of the reported resultLowLowLowLowLowSome concernsLowLowSome concernsLowSome concernsLowOverall risk of biasLowHighHighLowSome concernsHighSome concernsLowSome concernsSome concernsHighLow

Table 5Risk of bias (the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) assessment tool)AuthorSeuffertBeatonStuurman-BiezeRisk of BiasBias due to confoundingLowLowLowBias in selection of participants into the studyLowLowSeriousBias in classification of interventionsLowLowSeriousBias due to deviations from intended interventionsLowLowLowBias due to missing dataModerateModerateModerateBias in measurement of outcomesLowLowLowBias in selection of the reported resultLowLowLowOverall risk of biasModerateModerateSerious

Appendix 3 {#Sec23}
==========

Table 6Quality of the selected studiesConsort checklistArticlesConsort ItemRouxTuzunBianchiTitle and abstract1aIdentification as a randomized trial in the title-+-1bStructured summary of trial design, methods, results, and conclusions.+++Introduction2aScientific background and explanation of rationale+++2bSpecific objectives or hypotheses+++Methods3aDescription of trial design (such as parallel, factorial) including allocation ratio+++3bImportant changes to methods after trial commencement (such as eligibility criteria), with reasons\--+/-4aEligibility criteria for participants+++4bSettings and locations where the data were collected++/-+5The interventions for each group with sufficient details to allow replication, including how and when they were actually administered+++6aCompletely defined pre-specified primary and secondary outcome measures, including how and when they were assessed\]+++6bAny changes to trial outcomes after the trial commenced, with reasons-N/aN/a7aHow sample size was determined+\--7bWhen applicable, explanation of any interim analyses and stopping guidelines\--N/A8aMethod used to generate the random allocation sequence-++8bType of randomization; details of any restriction (such as blocking and block size)-++9Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned-++/-10Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions\-\--11aIf done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how\--N/a11bIf relevant, description of the similarity of interventions+++12aStatistical methods used to compare groups for primary and secondary outcomes+++12bMethods for additional analyses, such as subgroup analyses and adjusted analyses\--+Results13aFor each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome+++13bFor each group, losses and exclusions after randomization, together with reasons\-\--14aDates defining the periods of recruitment and follow-up+\--14bWhy the trial ended or was stopped\-\--15A table showing baseline demographic and clinical characteristics for each group-++/-16For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups++-17aFor each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)+++/-17bFor binary outcomes, presentation of both absolute and relative effect sizes is recommended++-18Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory\--N/a19All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)\-\--Discussion20Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses+++/-21Generalisability (external validity, applicability) of the trial findings++/-+/-22Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence+++/-Other information23Registration number and name of trial registry+-+24Where the full trial protocol can be accessed, if available+-+25Sources of funding and other support (such as supply of drugs), role of funders+++Consort checklistArticlesConsort ItemCramGonelliLeblancTitle and abstract1aIdentification as a randomized trial in the title+-+1bStructured summary of trial design, methods, results, and conclusions.+++Introduction2aScientific background and explanation of rationale+++2bSpecific objectives or hypotheses+++Methods3aDescription of trial design (such as parallel, factorial) including allocation ratio+++3bImportant changes to methods after trial commencement (such as eligibility criteria), with reasonsN/a\--4aEligibility criteria for participants+++/-4bSettings and locations where the data were collected++/-+5The interventions for each group with sufficient details to allow replication, including how and when they were actually administered+-/++6aCompletely defined pre-specified primary and secondary outcome measures, including how and when they were assessed\]+++6bAny changes to trial outcomes after the trial commenced, with reasonsN/aN/aN/a7aHow sample size was determined+-\_7bWhen applicable, explanation of any interim analyses and stopping guidelinesN/a\--8aMethod used to generate the random allocation sequence+-+8bType of randomization; details of any restriction (such as blocking and block size)+-+9Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned+-+10Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions+/\-\--11aIf done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how+-+11bIf relevant, description of the similarity of interventionsN/a++12aStatistical methods used to compare groups for primary and secondary outcomes+++12bMethods for additional analyses, such as subgroup analyses and adjusted analyses\-\--Results13aFor each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome+++13bFor each group, losses and exclusions after randomization, together with reasons+/\--+14aDates defining the periods of recruitment and follow-up-+/-+14bWhy the trial ended or was stopped\-\--15A table showing baseline demographic and clinical characteristics for each group+\--16For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups+/1++17aFor each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)-++17bFor binary outcomes, presentation of both absolute and relative effect sizes is recommendedN/a++18Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratoryN/a\--19All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)\-\--Discussion20Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses+++21Generalisability (external validity, applicability) of the trial findings+/-++22Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence+++Other information23Registration number and name of trial registry+-+24Where the full trial protocol can be accessed, if available+-+25Sources of funding and other support (such as supply of drugs), role of funders+-+Consort checklistArticlesConsort ItemDanilaStuurman-BiezeOralTitle and abstract1aIdentification as a randomized trial in the title+-+/-1bStructured summary of trial design, methods, results, and conclusions.+++Introduction2aScientific background and explanation of rationale++/-+2bSpecific objectives or hypotheses+++Methods3aDescription of trial design (such as parallel, factorial) including allocation ratio+++3bImportant changes to methods after trial commencement (such as eligibility criteria), with reasonsN/aN/aN/a4aEligibility criteria for participants+++4bSettings and locations where the data were collected+++/-5The interventions for each group with sufficient details to allow replication, including how and when they were actually administered++/-+6aCompletely defined pre-specified primary and secondary outcome measures, including how and when they were assessed\]+++/-6bAny changes to trial outcomes after the trial commenced, with reasonsN/aN/aN/a7aHow sample size was determined+\--7bWhen applicable, explanation of any interim analyses and stopping guidelines-N/aN/a8aMethod used to generate the random allocation sequence+-+8bType of randomization; details of any restriction (such as blocking and block size)+-+9Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned+\--10Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions+-+/-11aIf done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how+N/aN/a11bIf relevant, description of the similarity of interventions+N/aN/a12aStatistical methods used to compare groups for primary and secondary outcomes+++12bMethods for additional analyses, such as subgroup analyses and adjusted analyses+\--Results13aFor each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome+++13bFor each group, losses and exclusions after randomization, together with reasons+++14aDates defining the periods of recruitment and follow-up++-14bWhy the trial ended or was stoppedN/a+-15A table showing baseline demographic and clinical characteristics for each group++-16For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups+\--17aFor each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)+++17bFor binary outcomes, presentation of both absolute and relative effect sizes is recommended+++18Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory+N/a-19All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)\-\--Discussion20Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses++/-+/-21Generalisability (external validity, applicability) of the trial findings-++/-22Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence+++Other information23Registration number and name of trial registry+\--24Where the full trial protocol can be accessed, if available+\--25Sources of funding and other support (such as supply of drugs), role of funders+++Consort checklistArticlesConsort ItemTamechikaDucolombierTitle and abstract1aIdentification as a randomized trial in the title+-1bStructured summary of trial design, methods, results, and conclusions.++Introduction2aScientific background and explanation of rationale++/-2bSpecific objectives or hypotheses++Methods3aDescription of trial design (such as parallel, factorial) including allocation ratio+-3bImportant changes to methods after trial commencement (such as eligibility criteria), with reasons-N/a4aEligibility criteria for participants++4bSettings and locations where the data were collected++/-5The interventions for each group with sufficient details to allow replication, including how and when they were actually administered++6aCompletely defined pre-specified primary and secondary outcome measures, including how and when they were assessed\]++6bAny changes to trial outcomes after the trial commenced, with reasons-N/a7aHow sample size was determined++7bWhen applicable, explanation of any interim analyses and stopping guidelines-N/a8aMethod used to generate the random allocation sequence\--8bType of randomization; details of any restriction (such as blocking and block size)\--9Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned\--10Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions\--11aIf done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how-N/a11bIf relevant, description of the similarity of interventions+N/a12aStatistical methods used to compare groups for primary and secondary outcomes++12bMethods for additional analyses, such as subgroup analyses and adjusted analyses\--Results13aFor each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome++13bFor each group, losses and exclusions after randomisation, together with reasons+/-+/-14aDates defining the periods of recruitment and follow-up+-14bWhy the trial ended or was stopped\--15A table showing baseline demographic and clinical characteristics for each group-+16For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups+-17aFor each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)++17bFor binary outcomes, presentation of both absolute and relative effect sizes is recommended++18Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory\--19All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)\--Discussion20Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses++21Generalisability (external validity, applicability) of the trial findings++22Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence++Other information23Registration number and name of trial registry+-24Where the full trial protocol can be accessed, if available+-25Sources of funding and other support (such as supply of drugs), role of funders++Strobe checklistArticlesStrobe itemBeatonSeuffertTitle and abstract1aIndicate the study's design with a commonly used term in the title or the abstract++1bProvide in the abstract an informative and balanced summary of what was done and what was found++Introduction2Explain the scientific background and rationale for the investigation being reported++3State specific objectives, including any pre-specified hypotheses+/-+/-Methods4Present key elements of study design early in the paper++5Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection++6aGive the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up+/-+/-6bFor matched studies, give matching criteria and number of exposed and unexposedN/a-7Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable+/-+/-8For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group+-9Describe any efforts to address potential sources of bias\--10Explain how the study size was arrived at\--11Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why++/-12aDescribe all statistical methods, including those used to control for confounding++/-12bDescribe any methods used to examine subgroups and interactions+/-N/a12cExplain how missing data were addressed\--12d*Cohort study*---If applicable, explain how loss to follow-up was addressed*Case-control study*---If applicable, explain how matching of cases and controls was addressed*Cross-sectional study*---If applicable, describe analytical methods taking account of sampling strategy\--12eDescribe any sensitivity analyses\--Results13aReport numbers of individuals at each stage of study---eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed+/-+/-13bGive reasons for non-participation at each stage\--13cConsider use of a flow diagram+N/a14aGive characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders+/-+/-14bIndicate number of participants with missing data for each variable of interest\--14c*Cohort study*---Summarise follow-up time (eg, average and total amount)++15*Cohort study*---Report numbers of outcome events or summary measures over time-+*Case-control study---*Report numbers in each exposure category, or summary measures of exposureN/aN/a*Cross-sectional study---*Report numbers of outcome events or summary measuresN/aN/a16aGive unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included\--16bReport category boundaries when continuous variables were categorized-+16cIf relevant, consider translating estimates of relative risk into absolute risk for a meaningful time periodN/aN/a17Report other analyses done---eg analyses of subgroups and interactions, and sensitivity analyses\--Discussion18Summarise key results with reference to study objectives++19Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias++20Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence++21Discuss the generalizability (external validity) of the study results\--Other information22Other funding+-Consort checklistArticlesConsort ItemVan den bergGandaTitle and abstract1aIdentification as a randomized trial in the title-+1bStructured summary of trial design, methods, results, and conclusions.++Introduction2aScientific background and explanation of rationale++2bSpecific objectives or hypotheses++Methods3aDescription of trial design (such as parallel, factorial) including allocation ratio+/-+3bImportant changes to methods after trial commencement (such as eligibility criteria), with reasonsN/aN/a4aEligibility criteria for participants++4bSettings and locations where the data were collected+/-+5The interventions for each group with sufficient details to allow replication, including how and when they were actually administered++6aCompletely defined pre-specified primary and secondary outcome measures, including how and when they were assessed\]+/-+6bAny changes to trial outcomes after the trial commenced, with reasonsN/aN/a7aHow sample size was determined++7bWhen applicable, explanation of any interim analyses and stopping guidelines-N/a8aMethod used to generate the random allocation sequence++8bType of randomization; details of any restriction (such as blocking and block size)++9Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned-+10Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions+/-+/-11aIf done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how-N/a11bIf relevant, description of the similarity of interventions+N/a12aStatistical methods used to compare groups for primary and secondary outcomes++12bMethods for additional analyses, such as subgroup analyses and adjusted analyses++Results13aFor each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome++13bFor each group, losses and exclusions after randomisation, together with reasons++/-14aDates defining the periods of recruitment and follow-up+-14bWhy the trial ended or was stoppedN/a-15A table showing baseline demographic and clinical characteristics for each group+/-+16For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups+-17aFor each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)++17bFor binary outcomes, presentation of both absolute and relative effect sizes is recommended++18Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory++19All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)-N/aDiscussion20Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses++21Generalisability (external validity, applicability) of the trial findings+/-+/-22Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence++Other information23Registration number and name of trial registry++24Where the full trial protocol can be accessed, if available-+25Sources of funding and other support (such as supply of drugs), role of funders+-
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